Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.66 |
| ▸ | GSK3A | P49840 | 8/20 | 0.65 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RGS4 | P49798 | 1/20 | 0.35 |
| ▸ | RGS8 | P57771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015126 | 0.79 | GSK3B (1.00) | GSK3BGSK3APRKCAMAPK8PGR | |
| SCHEMBL3378575 | 0.77 | GSK3B (0.67) | GSK3BGSK3APRKCASMN1; SMN2RGS4 | |
| SCHEMBL3382652 | 0.65 | GSK3B (0.73) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL16041307 | 0.65 | GSK3B (0.74) | GSK3BGSK3APRKCACASP3 | |
| SCHEMBL16041304 | 0.65 | GSK3B (0.74) | GSK3BGSK3APRKCACASP3 | |
| SCHEMBL16041302 | 0.65 | GSK3B (0.74) | GSK3BGSK3APRKCACASP3 | |
| SCHEMBL3384015 | 0.64 | GSK3B (0.71) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL15354264 | 0.62 | GSK3B (1.00) | GSK3BGSK3APGRLMNATSHR | |
| SCHEMBL3383895 | 0.61 | GSK3B (0.67) | GSK3BGSK3APRKCALMNARGS4 | |
| SCHEMBL5306506 | 0.61 | MAPK1 (0.71) | GSK3BGSK3APGRLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781463-B2 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7666885-B2 | Neurodegenerative disease; anticancer agents; hyperplasia; arterosclerosis; restenosis; non-insulin dependent diabetis; Alzheimer's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-02-23 | — | — | US | disclosed |
| US-20080033012-A1 | Enzyme inhibitors | COSENJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033012-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885PRKCA 505/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885PRKCA 643/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885PRKCA 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.